Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | IDO1 | P14902 | 5/20 | 0.52 |
| ▸ | PNMT | P11086 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.48 |
| ▸ | HTR3B | O95264 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.48 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3395963 | 0.85 | PKM (0.74) | PKMIDO1PNMTTAAR1HTT | |
| SCHEMBL9629915 | 0.84 | PKM (0.71) | PKMIDO1TAAR1HTTLMNA | |
| SCHEMBL6896048 | 0.82 | PKM (0.68) | PKMIDO1PNMTMGLLTAAR1 | |
| SCHEMBL17938179 | 0.80 | PKM (0.67) | PKMIDO1PNMTMGLLTAAR1 | |
| SCHEMBL29858834 | 0.79 | PKM (0.66) | PKMIDO1PNMTMGLLTAAR1 | |
| SCHEMBL2944420 | 0.78 | PKM (0.64) | PKMIDO1PNMTTAAR1HTT | |
| SCHEMBL1091961 | 0.78 | PKM (0.64) | PKMIDO1PNMTTAAR1HTT | |
| Hydrochloric Acid SCHEMBL3244563 | 0.77 | PKM (0.62) | PKMIDO1PNMTTAAR1HTT | |
| Hydrochloric Acid SCHEMBL7827446 | 0.77 | PKM (0.62) | PKMIDO1PNMTTAAR1HTT | |
| SCHEMBL4276985 | 0.76 | PKM (0.61) | PKMIDO1PNMTTAAR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | ABBVIE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-9717709-B2 | Substituted pyrazoles as heat shock transcription factor activators | DUKE UNIVERSITY (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718784-B2 | Substituted pyrazoles as heat shock transcription factor activators | DUKE UNIVERSITY (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170000768-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | CHAPERONE THERAPEUTICS, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9447058-B2 | Substituted 1,3-thiazoles as heat shock transcription factor 1 activators | DUKE UNIVERSITY (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160221958-A1 | SUBSTITUTED PYRAZOLES AS HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATORS | DUKE UNIVERSITY | 2016-08-04 | — | — | US | disclosed |
| US-9315449-B2 | Substituted pyrazoles as heat shock transcription factor activators | DUKE UNIVERSITY (US) | 2016-04-19 | — | — | US | disclosed |
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160031880-A1 | Nampt and Rock Inhibitors | ABBVIE INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160024035-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY | 2016-01-28 | — | — | US | disclosed |
| CN-103313968-A | Nampt and rock inhibitors | ABBVIE LAB | 2013-09-18 | — | — | CN | disclosed |
| WO-2012067965-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2011-05-12 | — | — | US | disclosed |
| US-7265138-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265138-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265138-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1818333-A1 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1818333-A1 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20040157845-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221958-A1 | SUBSTITUTED PYRAZOLES AS HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATORS | HSF1, HSP90AB1, HSPBP1 | PKM 1354/4885IDO1 3939/4885PNMT 4222/4885 |
| US-20160024035-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | PKM 2073/4885IDO1 4613/4885PNMT 4535/4885 |
| US-10093624-B2 | NAMPT and ROCK inhibitors | NAMPT, NNMT, NADK | PKM 962/4885IDO1 826/4885PNMT 654/4885 |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | NAMPT, NNMT, NME2 | PKM 1206/4885IDO1 2379/4885PNMT 492/4885 |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | PKM 2073/4885IDO1 4613/4885PNMT 4535/4885 |
| US-20040157845-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | PKM 3270/4885IDO1 507/4885PNMT 2325/4885 |
| US-20160031880-A1 | Nampt and Rock Inhibitors | NAMPT, NNMT, NME2 | PKM 1206/4885IDO1 2379/4885PNMT 492/4885 |
| US-20170000768-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | PKM 2073/4885IDO1 4613/4885PNMT 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.